Absci Corporation Reports Strong Q4 2025 Earnings and Clinical Advancements

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 6 days ago

0mins

ABSI-0.72%

Should l Buy ABSI?

Source: seekingalpha

Clinical Advancements: Absci's ABS-201 has entered clinical trials with the first single ascending dose cohorts dosed, and preliminary safety data shows promise, indicating the drug's potential in treating androgenetic alopecia and endometriosis.
Financial Performance: The company reported $700,000 in revenue for Q4, with R&D expenses rising to $25.3 million, reflecting ongoing investment in internal programs, while ending the year with $144.3 million in cash and equivalents, ensuring operational funding for the coming years.
Strategic Outlook: Absci anticipates sharing preliminary safety and pharmacokinetic data for ABS-201 in the first half of 2026, with 13-week proof-of-concept data in the second half, and plans to initiate a Phase II clinical trial for endometriosis in Q4 2026.
Market Opportunity: Management highlighted a potential $25 billion annual addressable market for ABS-201 in the U.S., emphasizing the product's commercial prospects and market potential, while continuing discussions with pharmaceutical companies for platform partnerships.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ABSI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ABSI

Wall Street analysts forecast ABSI stock price to rise

7 Analyst Rating

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.760

Low

4.32

Averages

7.66

High

10.00

Current: 2.760

Low

4.32

Averages

7.66

High

10.00

Morgan Stanley

Equal Weight

downgrade

2026-03-25

Reason

Morgan Stanley

Price Target

AI Analysis

2026-03-25

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Absci to $4.20 from $4.32 and keeps an Equal Weight rating on the shares after the company reported Q4 earnings and updates. The firm updated its model for the quarter and full year and adjusted its revenue estimates for ABS-201 slightly, the analyst noted.

Morgan Stanley

Overweight -> Equal Weight

downgrade

2026-01-08

Reason

Morgan Stanley

Price Target

2026-01-08

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley downgraded Absci to Equal Weight from Overweight with a price target of $4.32, down from $5.80. The latest company and pipeline disclosures have meaningfully increased the risk profile and reduced the visibility of near-term, value-accretive execution, contends the analyst, who is updating the firm's valuation and risk framework and, in doing so, lowering its price target and rating.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABSI

Unlock Now

About ABSI

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Absci (ABSI) Q4 2025 Earnings Call Transcript

6 days agoNASDAQ.COM

ABSCI STOCK DROPS 4.9% FOLLOWING Q4 RESULTS

6 days agomoomoo

Company Performance: The company reported a 4.9% decline in its stock value following the release of its Q4 results.
Market Reaction: Investors reacted negatively to the earnings report, leading to a significant drop in share prices.
Future Outlook: Analysts are concerned about the implications of the Q4 results on the company's future performance and growth potential.
Investor Sentiment: The decline in stock value reflects a broader uncertainty among investors regarding the company's strategic direction.

Absci Corp Reports Q4 Highlights and Future Prospects

6 days agoYahoo Finance

Financial Performance: In Q4 2025, Absci Corp reported revenue of $700,000, with R&D expenses rising to $25.3 million from $18.4 million year-over-year, indicating a commitment to innovation despite potential short-term profitability pressures due to increased spending.
Cash Position: As of December 31, 2025, the company held $144.3 million in cash, cash equivalents, and marketable securities, down from $152.5 million on September 30, 2025, yet sufficient to fund operations into the first half of 2028, reflecting strong financial management.
Clinical Progress: ABS-201 is showing promising results in clinical trials with favorable emerging safety data and has expanded into endometriosis, a second multibillion-dollar indication, highlighting its market potential and potential new revenue streams for the company.
Market Competition: The success of ABS-201 hinges on achieving efficacy comparable to or exceeding high-dose oral minoxidil, while the company faces significant competition in the androgenetic alopecia market, with other treatments gaining traction that could impact its market share.